Evidence map›Paper›PMID 35347560›Full record

ReviewCurrent treatment options in oncology2022

Current Treatment Options for Cutaneous Adnexal Malignancies.

Hiroyuki Goto

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Hiroyuki GotoDivision of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, 36-1, Nishicho, Yonago, Tottori, 683-8503, Japan. higoto@tottori-u.ac.jp.ORCID 0000-0001-6744-6291
Tottori University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementCutaneous adnexal malignancies include various types of malignant tumors that show differentiation of cutaneous appendages. They can be classified into sweat gland, hair follicle, and sebaceous gland differentiations. All types of cutaneous adnexal tumors are rare and standard treatment options based on valid evidence have not been established. Although prognosis differs depending on the type of cutaneous adnexal malignancy, surgery is the mainstay of treatment. In surgical treatment, an adequate surgical margin is unclear for wide local excision. Mohs micrographic is a better option than wide local excision in terms of margin control and cosmetic outcome because the face, head, and neck are favorable sites for some cutaneous adnexal malignancies. There has been no randomized trial of radiation therapy and chemotherapy for any cutaneous adnexal malignancies. Radiation therapy should be considered if the tumor cannot be removed surgically. Chemotherapy is one of the options for metastatic cases in some types of cutaneous adnexal malignancies, but evidence of the effectiveness of chemotherapy is lacking. Recent studies have revealed genetic mutations in this field, and target therapy and immunotherapy may be promising treatment options for unresectable cutaneous adnexal malignancies in the future.

Indexed as

Skin NeoplasmsHumansPrognosisSkinChemotherapyCutaneous adnexal malignancyMetastasisRadiation therapySurgery

Identifiers

PMID35347560
OpenAlexW4221042350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.